The addition of 30 mg of evenamide to patients’ current antipsychotic medication was associated with a highly statistically significant reduction in the PANSS Total Score.
Contrasting Newron Pharmaceuticals (OTCMKTS:NWPHF) and Tenax Therapeutics (NASDAQ:TENX) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Study results
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual.
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) 08.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia for up to one year
Presentation of study design for potentially.